CD274 and head and neck squamous cell carcinoma: Here we report results from a phase I study of durvalumab combined with tremelimumab in treatment-naive or previously treated patients [including those refractory to PD-(L)1 inhibitors] with R/M HNSCC (ClinicalTrials.gov NCT02262741).